6921-45-5

Basic information

• Product Name: Ethanone, 1-(4-cyclopropylphenyl)- (9CI)
• Synonyms: Ethanone, 1-(4-cyclopropylphenyl)- (9CI);Ethanone,1-(4-cyclopropylphenyl)-
• CAS NO: 6921-45-5
• Molecular Formula: C₁₁H₁₂O
• Molecular Weight: 160.21238
• Product Categories: ACETYLGROUP
• Mol File: 6921-45-5.mol
• Article Data: 17

Chemical Properties

• Melting Point: 35-36 °C(Solv: ethanol (64-17-5))
• Boiling Point: 271.6°C at 760 mmHg
• Flash Point: 112.3°C
• Appearance: /
• Density: 1.075g/cm³
• Vapor Pressure: 0.00641mmHg at 25°C
• Refractive Index: 1.562
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: Ethanone, 1-(4-cyclopropylphenyl)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Ethanone, 1-(4-cyclopropylphenyl)- (9CI)(6921-45-5)
• EPA Substance Registry System: Ethanone, 1-(4-cyclopropylphenyl)- (9CI)(6921-45-5)

Safety Data

• Hazardous Substances Data: 6921-45-5(Hazardous Substances Data)

Usage

General Description

Ethanone, 1-(4-cyclopropylphenyl)- (9CI) is a chemical compound commonly used in various fields such as biochemistry and pharmaceuticals. It is characterized by a keto group (ethanone) attached to a phenyl ring that contains a cyclopropyl group. The compound is known for its chemical stability and reactivity, making it useful for a multitude of chemical reactions and preparations. The '9CI' signifies that it is listed in the Ninth Collective Index (9CI), an extensive index of chemical compounds. Like most chemicals, its usage requires caution due to potential safety issues.

InChI:InChI=1/C11H12O/c1-8(12)9-2-4-10(5-3-9)11-6-7-11/h2-5,11H,6-7H2,1H3

Upstream product

• 873-49-4 cyclopropylbenzene 
• 10537-63-0 1-(4-vinylphenyl)ethanone 
• 925430-09-7 tricyclopropylbismuthane 
• 13329-40-3 4-Iodoacetophenone 
• 201230-82-2 carbon monoxide 
• 75-11-6 diiodomethane 
• 99-91-2 para-chloroacetophenone 
• 99-90-1 para-bromoacetophenone 
• 19936-09-5 2-(4-cyclopropylphenyl)-2-propanol 
• 1144509-67-0 2-(4-cyclopropylphenyl)-2-propoxyl 
• 109613-00-5 4-acetophenyl triflate 
• 4333-56-6 cyclopropyl bromide 
• 411235-57-9 cyclopropylboronic acid 
• 23719-81-5 tri(cyclopropyl)indium 

Downstream Products

• 1798-82-9 4-cyclopropylbenzoic acid 
• 120109-73-1 (Z)-2-Cyano-3-(4-cyclopropyl-phenyl)-but-2-enoic acid ethyl ester 
• 40641-97-2 α-(p-Cyclopropylphenyl)aethanol 
• 55829-69-1 1-Cyclopropyl-4-(1-phenyl-vinyl)-benzene 
• 55829-71-5 1-[1-(4-Cyclopropyl-phenyl)-vinyl]-3,5-bis-trifluoromethyl-benzene 
• 55829-70-4 C₁₈H₁₅F₃ 
• 73005-35-3 (2,4-dinitrophenyl)hydrazone of p-cyclopropylacetophenone 
• 138354-30-0 2,3-Bis-(4-cyclopropyl-phenyl)-butane-2,3-diol 
• 19936-11-9 N-(4-cyclopropylphenyl)acetamide 
• 19936-10-8 p-cyclopropyl-α-methylstyrene 
• 40641-91-6 4-[(4-cyclopropyl-phenyl)-thioacetyl]-morpholine 

Relevant articles and documents

CARBAMATE DERIVATIVES AND USES THEREOF

The present disclosure relates to compounds of Formula (I): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.

Palladium-Catalyzed Carbonylative Cross-Coupling Reaction between Aryl(Heteroaryl) Iodides and Tricyclopropylbismuth: Expedient Access to Aryl Cyclopropylketones

The carbonylative cross-coupling reaction between aryl and heteroaryl iodides and tricyclopropylbismuth is reported. The reaction is catalyzed by (SIPr)Pd(allyl)Cl, a NHC-palladium(II) catalyst, operates under 1 atm of carbon monoxide and tolerates a wide range of functional groups. The use of lithium chloride was found to provide higher yields of the desired aryl cyclopropylketones. The conditions were also applied to the carbonylative cross-coupling of an iodoalkene to afford the corresponding alkenyl cyclopropylketone.

OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF

The present disclosure relates to oxadiazine compounds, pharmaceutical compositions comprising an effective amount of an oxadiazine compound and methods for using an oxadiazine compound in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of an oxadiazine compound.